Regent Pacific Group Limited (0575.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In HKD
Sector
Financial Services
Industry
Asset Management
Employees
18
First IPO Date
May 19, 1997
| Name | Title | Pay | Year Born |
| Jamie Alexander Gibson | Chief Executive Officer & Executive Director | 11.42M | 1966 |
| Michael Grant Wyllie | Co-Founder & Chief Scientific Officer | 1.62M | 1951 |
| Paul Eric Jones | Investment Director | 0 | 1965 |
| Yui Fui Wong | Chief Financial Officer | 0 | 1975 |
| Mei Yan Lui | Company Secretary | 0 | 1975 |
| John Michael Fitzpatrick MCh FRCSI Urol FRCSGlas FRCS | Chairman of Clinical Scientific Advisory Board | 0 | N/A |
Endurance RP Limited functions as an investment holding company, concentrating its investments within the healthcare and life sciences sectors across the People's Republic of China, Europe, Hong Kong, and Taiwan. The firm organizes its activities into two primary divisions: Biopharma and Corporate Investment. The Biopharma segment is responsible for the research, development, production, promotion, and distribution of pharmaceutical products aimed at addressing and managing urological disorders. This division also innovates artificial intelligence systems to precisely track the pace of aging, examining it at molecular, cellular, tissue, organ, systemic, physiological, and psychological levels. Through its Corporate Investment division, the company strategically invests in both publicly traded and privately held corporate entities. Additionally, it extends its services to include management consulting and corporate financial advice. Incorporated in 1991 and headquartered in Central, Hong Kong, Endurance RP Limited adopted its current name in June 2021, having previously operated as Regent Pacific Group Limited.